Mucin (Muc) expression during pancreatic cancer progression in spontaneous mouse model: Potential implications for diagnosis and therapy

Journal of Hematology and Oncology

Volumn 5, Issue , 2012, Pages

  Rachagani, Satyanarayana ^a   Torres, María P ^a,b   Kumar, Sushil ^a   Haridas, Dhanya ^a   Baine, Michael ^a   MacHa, Muzafar A ^a   Kaur, Sukhwinder ^a   Ponnusamy, Moorthy P ^a   Dey, Parama ^a   Seshacharyulu, Parthasarathy ^a   Johansson, Sonny L ^a   Jain, Maneesh ^a   Wagner, Kay Uwe ^b   Batra, Surinder K ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Inflammatory cytokines; KrasG12D mouse model; Mucins

Indexed keywords

CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; GAMMA INTERFERON; MESSENGER RNA; MUCIN 1; MUCIN 4; MUCIN 5AC;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER MODEL; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE RELEASE; GENE EXPRESSION; GENE EXPRESSION PROFILING; IMMUNOHISTOCHEMISTRY; MACROPHAGE MIGRATION; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS ADENOMA; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, TRANSGENIC; MUCINS; PANCREATIC NEOPLASMS; RNA, MESSENGER;

EID: 84867801436     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-5-68     Document Type: Article

References (49)

1. Cancer statistics, 2012. Siegel R, Naishadham D, Jemal A, CA Cancer J Clin 2012 62 10 29 10.3322/caac.20138 22237781
2. Pancreatic cancer registry in Japan: 20years of experience. Matsuno S, Egawa S, Fukuyama S, Motoi F, Sunamura M, Isaji S, et al. Pancreas 2004 28 219 230 10.1097/00006676-200404000-00002 15084961 (Pubitemid 38437313)
3. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses. Sultana A, Tudur SC, Cunningham D, Starling N, Neoptolemos JP, Ghaneh P, Br J Cancer 2008 99 6 13 10.1038/sj.bjc.6604436 18577990 (Pubitemid 351920234)
4. Molecular markers of pancreatic cancer: development and clinical relevance. Fry LC, Monkemuller K, Malfertheiner P, Langenbecks Arch Surg 2008 393 883 890 10.1007/s00423-007-0276-0 18266003
5. MUC4 mucin potentiates pancreatic tumor cell proliferation, survival, and invasive properties and interferes with its interaction to extracellular matrix proteins. Chaturvedi P, Singh AP, Moniaux N, Senapati S, Chakraborty S, Meza JL, et al. Mol Cancer Res 2007 5 309 320 10.1158/1541-7786.MCR-06-0353 17406026 (Pubitemid 46706993)
6. Multiple roles of mucins in pancreatic cancer, a lethal and challenging malignancy. Moniaux N, Andrianifahanana M, Brand RE, Batra SK, Br J Cancer 2004 91 1633 1638 15494719 (Pubitemid 39546133)
7. Aberrant expression of MUC4 in ovarian carcinoma: diagnostic significance alone and in combination with MUC1 and MUC16 (CA125). Chauhan SC, Singh AP, Ruiz F, Johansson SL, Jain M, Smith LM, et al. Mod Pathol 2006 19 1386 1394 10.1038/modpathol.3800646 16880776 (Pubitemid 44423087)
8. Mucins in cancer: protection and control of the cell surface. Hollingsworth MA, Swanson BJ, Nat Rev Cancer 2004 4 45 60 10.1038/nrc1251 14681689 (Pubitemid 38082153)
9. Mucin-based targeted pancreatic Cancer Therapy. Torres MP, Chakraborty S, Souchek J, Batra SK, Curr Pharm Des 2012 18 17 2472 2481 10.2174/ 13816128112092472 22372499
10. Mucin (MUC) gene expression in human pancreatic adenocarcinoma and chronic pancreatitis: a potential role of MUC4 as a tumor marker of diagnostic significance. Andrianifahanana M, Moniaux N, Schmied BM, Ringel J, Friess H, Hollingsworth MA, et al. Clin Cancer Res 2001 7 4033 4040 11751498 (Pubitemid 34044624)
11. Biomarkers in Diagnosis of pancreatic carcinoma in fine-needle aspirates. Jhala N, Jhala D, Vickers SM, Eltoum I, Batra SK, Manne U, et al. Am J Clin Pathol 2006 126 572 579 10.1309/CEV30BE088CBDQD9 17019794
12. Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Iacobuzio-Donahue CA, Ashfaq R, Maitra A, Adsay NV, Shen-Ong GL, Berg K, et al. Cancer Res 2003 63 8614 8622 14695172 (Pubitemid 38064035)
13. Associations between selected biomarkers and prognosis in a population-based pancreatic cancer tissue microarray. Takikita M, Altekruse S, Lynch CF, Goodman MT, Hernandez BY, Green M, et al. Cancer Res 2009 69 2950 2955 10.1158/0008-5472.CAN-08-3879 19276352
14. Differentiation markers in pancreatic head adenocarcinomas: MUC1 and MUC4 expression indicates poor prognosis in pancreatobiliary differentiated tumours. Westgaard A, Schjolberg AR, Cvancarova M, Eide TJ, Clausen OP, Gladhaug IP, Histopathology 2009 54 337 347 10.1111/j.1365-2559.2009.03227.x 19236510
15. MUC4 is a novel prognostic factor of extrahepatic bile duct carcinoma. Tamada S, Shibahara H, Higashi M, Goto M, Batra SK, Imai K, et al. Clin Cancer Res 2006 12 4257 4264 10.1158/1078-0432.CCR-05-2814 16857800
16. Cloning and sequencing of a human pancreatic tumor mucin cDNA. Lan MS, Batra SK, Qi WN, Metzgar RS, Hollingsworth MA, J Biol Chem 1990 265 15294 15299 2394722
17. Delayed mammary tumor progression in Muc-1 null mice. Spicer AP, Rowse GJ, Lidner TK, Gendler SJ, J Biol Chem 1995 270 30093 30101 10.1074/jbc.270.50. 30093 8530414 (Pubitemid 26001684)
18. MUC1 enhances tumor progression and contributes toward immunosuppression in a mouse model of spontaneous pancreatic adenocarcinoma. Tinder TL, Subramani DB, Basu GD, Bradley JM, Schettini J, Million A, et al. J Immunol 2008 181 3116 3125 18713982
19. Significance of mucin expression in pancreatobiliary neoplasms. Yonezawa S, Higashi M, Yamada N, Yokoyama S, Goto M, J Hepatobiliary Pancreat Sci 2010 17 108 124 10.1007/s00534-009-0174-7 19787286
20. MUC4 mucin interacts with and stabilizes the HER2 oncoprotein in human pancreatic cancer cells. Chaturvedi P, Singh AP, Chakraborty S, Chauhan SC, Bafna S, Meza JL, et al. Cancer Res 2008 68 2065 2070 10.1158/0008-5472.CAN-07- 6041 18381409 (Pubitemid 351521776)
21. RNA interference suppression of MUC1 reduces the growth rate and metastatic phenotype of human pancreatic cancer cells. Tsutsumida H, Swanson BJ, Singh PK, Caffrey TC, Kitajima S, Goto M, et al. Clin Cancer Res 2006 12 2976 2987 10.1158/1078-0432.CCR-05-1197 16707592 (Pubitemid 43837341)
22. Structure, evolution, and biology of the MUC4 mucin. Chaturvedi P, Singh AP, Batra SK, FASEB J 2008 22 966 981 18024835 (Pubitemid 351519954)
23. Cloning of rat Muc5AC mucin gene: comparison of its structure and tissue distribution to that of human and mouse homologues. Inatomi T, Tisdale AS, Zhan Q, Spurr-Michaud S, Gipson IK, Biochem Biophys Res Commun 1997 236 789 797 10.1006/bbrc.1997.7051 9245735 (Pubitemid 27384711)
24. Complete sequence of the human mucin MUC4: a putative cell membrane-associated mucin. Moniaux N, Nollet S, Porchet N, Degand P, Laine A, Aubert JP, Biochem J 1999 338 Pt 2 325 333 10024507
25. Molecular cloning and analysis of the mouse homologue of the tumor-associated mucin, MUC1, reveals conservation of potential O-glycosylation sites, transmembrane, and cytoplasmic domains and a loss of minisatellite-like polymorphism. Spicer AP, Parry G, Patton S, Gendler SJ, J Biol Chem 1991 266 15099 15109 1714452 (Pubitemid 21907624)
26. Genetics and biology of pancreatic ductal adenocarcinoma. Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, DePinho RA, Genes Dev 2006 20 1218 1249 10.1101/gad.1415606 16702400 (Pubitemid 43727584)
27. Graviola: A novel promising natural-derived drug that inhibits tumorigenicity and metastasis of pancreatic cancer cells in vitro and in vivo through altering cell metabolism. Torres MP, Rachagani S, Purohit V, Pandey P, Joshi S, Moore ED, et al. Cancer Lett 2012 323 1 29 40 10.1016/j.canlet.2012.03. 031 22475682
28. Human MUC4 mucin induces ultra-structural changes and tumorigenicity in pancreatic cancer cells. Moniaux N, Chaturvedi P, Varshney GC, Meza JL, Rodriguez-Sierra JF, Aubert JP, et al. Br J Cancer 2007 97 345 357 10.1038/sj.bjc.6603868 17595659 (Pubitemid 47196741)
29. Mucin expression profile in pancreatic cancer and the precursor lesions. Nagata K, Horinouchi M, Saitou M, Higashi M, Nomoto M, Goto M, et al. J Hepatobiliary Pancreat Surg 2007 14 243 254 10.1007/s00534-006-1169-2 17520199 (Pubitemid 46863913)
30. NF-kappaB in pancreatic cancer. Sclabas GM, Fujioka S, Schmidt C, Evans DB, Chiao PJ, Int J Gastrointest Cancer 2003 33 15 26 10.1385/IJGC:33:1:15 12909735
31. K-ras activation generates an inflammatory response in lung tumors. Ji H, Houghton AM, Mariani TJ, Perera S, Kim CB, Padera R, et al. Oncogene 2006 25 2105 2112 10.1038/sj.onc.1209237 16288213
32. IFN-gamma-induced expression of MUC4 in pancreatic cancer cells is mediated by STAT-1 upregulation: a novel mechanism for IFN-gamma response. Andrianifahanana M, Singh AP, Nemos C, Ponnusamy MP, Moniaux N, Mehta PP, et al. Oncogene 2007 26 7251 7261 10.1038/sj.onc.1210532 17525742 (Pubitemid 350085321)
33. Neutrophil elastase increases MUC5AC mRNA and protein expression in respiratory epithelial cells. Voynow JA, Young LR, Wang Y, Horger T, Rose MC, Fischer BM, Am J Physiol 1999 276 835 L843 10330040
34. Mucin glycosylation is altered by pro-inflammatory signaling in pancreatic-cancer cells. Wu YM, Nowack DD, Omenn GS, Haab BB, J Proteome Res 2009 8 1876 1886 10.1021/pr8008379 19714813
35. Current status of mucins in the diagnosis and therapy of cancer. Rachagani S, Torres MP, Moniaux N, Batra SK, Biofactors 2009 35 509 527 10.1002/biof.64 19904814
36. Current status of molecular markers for early detection of sporadic pancreatic cancer. Chakraborty S, Baine MJ, Sasson AR, Batra SK, Biochim Biophys Acta 2011 1815 44 64 20888394
37. Using genetically engineered mouse models of cancer to aid drug development: an industry perspective. Singh M, Johnson L, Clin Cancer Res 2006 12 5312 5328 10.1158/1078-0432.CCR-06-0437 17000664 (Pubitemid 44497244)
38. Cloning, chromosomal localization and characterization of the murine mucin gene orthologous to human MUC4. Desseyn JL, Clavereau I, Laine A, Eur J Biochem 2002 269 3150 3159 10.1046/j.1432-1033.2002.02988.x 12084055 (Pubitemid 34748101)
39. Transcriptional activation of the murine Muc5ac mucin gene in epithelial cancer cells by TGF-beta/Smad4 signalling pathway is potentiated by Sp1. Jonckheere N, Van Der Sluis M, Velghe A, Buisine MP, Sutmuller M, Ducourouble MP, et al. Biochem J 2004 377 797 808 14570593 (Pubitemid 38221854)
40. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, et al. Cancer Cell 2003 4 437 450 10.1016/S1535-6108(03)00309-X 14706336 (Pubitemid 38050041)
41. MUC1 as a target antigen for cancer immunotherapy. Acres B, Limacher JM, Expert Rev Vaccines 2005 4 493 502 10.1586/14760584.4.4.493 16117706 (Pubitemid 41297296)
42. Concomitant pancreatic activation of Kras(G12D) and Tgfa results in cystic papillary neoplasms reminiscent of human IPMN. Siveke JT, Einwachter H, Sipos B, Lubeseder-Martellato C, Kloppel G, Schmid RM, Cancer Cell 2007 12 266 279 10.1016/j.ccr.2007.08.002 17785207 (Pubitemid 47333415)
43. Pancreatic ductal adenocarcinoma mice lacking mucin 1 have a profound defect in tumor growth and metastasis. Besmer DM, Curry JM, Roy LD, Tinder TL, Sahraei M, Schettini J, et al. Cancer Res 2011 71 4432 4442 10.1158/0008-5472. CAN-10-4439 21558393
44. Mucins in human neoplasms: Clinical pathology, gene expression and diagnostic application. Yonezawa S, Higashi M, Yamada N, Yokoyama S, Kitamoto S, Kitajima S, et al. Pathol Int 2011 61 697 716 10.1111/j.1440-1827.2011.02734.x 22126377
45. MUC4 expression increases progressively in pancreatic intraepithelial neoplasia. Swartz MJ, Batra SK, Varshney GC, Hollingsworth MA, Yeo CJ, Cameron JL, et al. Am J Clin Pathol 2002 117 791 796 10.1309/7Y7N-M1WM-R0YK-M2VA 12090430 (Pubitemid 34457016)
46. RNA interference suppression of mucin 5AC (MUC5AC) reduces the adhesive and invasive capacity of human pancreatic cancer cells. Yamazoe S, Tanaka H, Sawada T, Amano R, Yamada N, Ohira M, et al. J Exp Clin Cancer Res 2010 29 53 53 10.1186/1756-9966-29-53 20492722
47. Kras(G12D)-induced IKK2/beta/NF-kappaB activation by IL-1alpha and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Ling J, Kang Y, Zhao R, Xia Q, Lee DF, Chang Z, et al. Cancer Cell 2012 21 105 120 10.1016/j.ccr.2011.12.006 22264792
48. Neutrophil elastase stimulates MUC1 gene expression through increased Sp1 binding to the MUC1 promoter. Kuwahara I, Lillehoj EP, Hisatsune A, Lu W, Isohama Y, Miyata T, et al. Am J Physiol Lung Cell Mol Physiol 2005 289 355 L362 10.1152/ajplung.00040.2005 15849214 (Pubitemid 41008920)
49. Molecular biology of pancreatic ductal adenocarcinoma progression: aberrant activation of developmental pathways. Rhim AD, Stanger BZ, Prog Mol Biol Transl Sci 2010 97 41 78 21074729